Rhythm Pharmaceuticals Key Takeaways

This report summarizes key takeaways from a meeting with Rhythm Pharmaceuticals (RYTM) management at the 47th Annual Global Healthcare Conference, focusing on the ongoing HO launch, PWS data, and pipeline updates. Goldman Sachs maintains a Buy rating with a $159 price target.

Key Takeaways

• 1.Management projects continued progress in the HO (Hypothalamic Obesity) launch with favorable reimbursement and adherence trends expected.
• 2.PWS (Prader-Willi Syndrome) clinical data is expected at ENDO 2026, which will help clarify Phase 3 trial designs.
• 3.Next-gen asset RM-718 is focusing on HO development, with initial data anticipated in 2Q26.

Table of Contents

• Key Takeaways
• Valuation/Risks
• Disclosure Appendix
• GS Factor Profile
• M&A Rank
• Quantum
• Disclosures
• Price target and rating history chart(s)
• Target price history table(s)
• Regulatory disclosures

Document Preview

Page 1 of 1

Subscribe for full accessStart Free Trial